- CP-640186
-
- $32.00
-
2026-07-21
- CAS:591778-68-6
- Purity: 98.28%
- Supply Ability: 10g
- CP 640186
-
- $1.00
-
2020-01-03
- CAS:591778-68-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200kg
|
| | CP 640186 Basic information |
| Product Name: | CP 640186 | | Synonyms: | CP 640186 (R)-ANTHRACEN-9-YL(3-(MORPHOLINE-4-CARBONYL)-1,4'-BIPIPERIDIN-1'-YL)METHANONE.HCL;(Anthracen-9-yl)[(3R)-3-[(morpholin-4-yl)carbonyl][1,4']bipiperidinyl-1'-yl]methanone;(R)-Anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)methanone;[(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone;CP 640186;(R)-ANTHRACEN-9-YL(3-(MORPHOLINE-4-CARBONYL)-1,4'-BIPIPERIDIN-1'-YL)METHANONE.HCL;(R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)metha none CP640186;CS-1316 | | CAS: | 591778-68-6 | | MF: | C30H35N3O3 | | MW: | 485.62 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 591778-68-6.mol |  |
| | CP 640186 Chemical Properties |
| Boiling point | 721.1±60.0 °C(Predicted) | | density | 1.245±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 10 mg/ml | | form | A crystalline solid | | pka | 8.07±0.40(Predicted) | | color | Light yellow to light brown |
| | CP 640186 Usage And Synthesis |
| Uses | CP 640186 can be used to regulate porcine reproductive and respiratory syndrome virus infection via the AMPK-ACC1 signaling pathway. | | Definition | ChEBI: (3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine is a member of anthracenes, a member of morpholines, a member of bipiperidines and a N-acylpiperidine. | | in vivo | CP-640186 (oral gavage; 4.6-21 mg/kg; once) demonstrates acute efficacy[1].
CP-640186 (intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once) shows lowe drug exposure in the rat than the ob/ob mouse at equal doses[1].
CP-640186 (oral gavage; 100 mg/kg; once) treatment shows a complete shift from carbohydrate utilization to fatty acid utilization as a source of energy at high exposure level[1]. | Animal Model: | Male ob/ob mice[1] | | Dosage: | 4.6-21 mg/kg | | Administration: | Oral gavage; 4.6-21 mg/kg; once | | Result: | Demonstrated acute efficacy for up to 8 h after oral administration, exhibiting ED50 values of 4.6, 9.7, and 21 mg/kg, at 1, 4, and 8 h, respectively, after treatment. |
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg | | Administration: | Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once | | Result: | Showed a plasma half-life of 1.5 h, a bioavailability of 39%, a Clp of 65 ml/min/kg, a Vdss of 5 liters/kg, an oral Tmax of 1.0 h, an oral Cmax of 345 ng/mL, and an oral AUC0-∞ of 960 ngh/mL. |
| Animal Model: | Male ob/ob mice[1] | | Dosage: | Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg | | Administration: | Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once | | Result: | Showed a plasma half-life of 1.1 h, a bioavailability of 50%, a Clp of 54 ml/min/kg, an oral Tmax of 0.25 h, an oral Cmax of 2177 ng/mL, and an oral AUC0-∞ of 3068 ngh/mL. |
| Animal Model: | Twenty male Sprague-Dawley rats (350-400 g) fasted and then refed a high sucrose diet for 2 days; additional eight rats fasted for 24 h[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; 100 mg/kg; once | | Result: | Resulted in time-dependent reductions in RQ (a ratio of CO2 production to O2 consumption) of up to 64%. |
|
| | CP 640186 Preparation Products And Raw materials |
|